CBUS · Cibus, Inc.
$1.61
+0.06 (+3.87%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Market Cap
$118.46M
Shares
76.43M
Volume · Sep 30
276.27K
Avg daily vol (3M)
236.37K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.61
Open$1.58
Day$1.58–1.74
52W close$1.16–4.05
Avg vol 30d112K
Short int3.5M · 4.5% float · 31.9d
Short vol47%
Last earningsAug 13, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$4.35M
Trailing 12 months
Net income (TTM)
−$98.19M
Trailing 12 months
Revenue growth YoY
+6.5%
Year over year
Operating margin
-1,450.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+84.4%
Year over year · more shares
Price change (1Y)
+18.3%
Trailing year
Short interest
4.5%
Latest settlement · 31.9 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. Q2 revenue rose 35% YTD on biofragrance ramp; rice commercial launch in Latin America pushed from late 2027 to 2028; net cash burn guidance raised to ~$35M exiting 2026; EU finalized rules treating gene-edited crops with no foreign DNA as conventional, and Interoc relationship expanded from two to five rice traits.
Bullish
- + YTD revenue up 35% YoY driven by Sustainable Ingredients program.
- + Biofragrance opportunity sized at $20-40M peak annual revenue.
- + Interoc rice relationship expanded from two to five traits, deepening the pipeline model.
- + EU finalized rules treating most gene-edited crops (no foreign DNA) as conventional, opening a major market.
- + FDA completed review of altered-lignin alfalfa trait with no further questions; USDA-APHIS confirmed Cibus traits are not regulated articles.
Bearish
- − Latin American rice commercial launch timing pushed from late 2027 to 2028.
- − Cash of $20.4M only funds operations into early Q1 2027 absent new financing.
- − Non-cash royalty liability interest expense rose to $9.5M (from $8.7M) and remains the largest gap between operating and net loss.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−15%
below
Price vs 50-day avg
−5%
below
RSI (14)
51
neutral
MACD trend
Positive
52-week position
16%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+28%
trailing
YTD return
−7%
this year
Relative strength
+16%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.52% of float · ▼ -0.5% MoM · 31.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
63 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−15%
Y/Y
Gross margin
4%
expanding
EPS growth
+74%
Y/Y
Free cash flow
$-51.2M
Balance sheet
$9.4M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 13, 2026
Annual net cash usage run-rate
· exiting 2026
$35M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−15%
Bearish
Price vs 50-day avg
−5%
Bearish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
16%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-9% holders QoQ · +13 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.52% of float · ▼ -0.5% MoM · 31.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
63 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 16%
Range high $4
vs 200-day avg -15%
vs 50-day avg -5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| annual net cash usage run-rate exiting 2026 | $35M | Q2 2026 | — |
| patents and patent applications | 500 | Q2 2026 | — |
| peak annual addressable royalty opportunity (Rice, LATAM) | $200M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CBUS
this stock
Cibus, Inc.
|
$118.46M | -7.5% | -14.6% | — | 4.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CBUS | +4.6% | +3.2% | +27.8% | -0.6% | -7.5% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +5.2% | +3.1% | +15.6% | 0.0% | -19.3% |